rss Posted August 22, 2014 Report Share Posted August 22, 2014 Non-Obligatory Role of Prostaglandin D2 Receptor Subtype 1 in Rosacea: Laropripant in Comparison to a Placebo Did Not Alleviate the symptoms of Erythematoelangiectaic Rosacea. J Clin Pharmacol. 2014 Aug 20; Authors: Krishna R, Guo Y, Schulz V, Cord-Cruz E, Smith S, Hair S, Nahm WK, Draelos ZD Abstract Erythematotelangiectatic rosacea shares facial flushing features with those seen after niacin. This study was performed to test the hypothesis whether prostaglandin D2 (PGD2) receptor subtype 1 antagonist (MK-0524) will improve the symptoms of rosacea. The purpose of this study was to evaluate the effect of MK-0524 100â€‰mg administered once daily for 4 weeks on the signs and symptoms of erythematotelangiectatic rosacea. Subjects received MK-0524 100â€‰mg once-daily (nâ€‰=â€‰30) or placebo (nâ€‰=â€‰30) for 4 weeks. The primary pharmacodynamics endpoint was change in Clinician's Erythema Assessment (CEA) score from Baseline to Week 4. The Patient Self-Assessment (PSA) was a secondary endpoint. MK-0524 was generally well tolerated in this study For the primary endpoint of change in CEA score from Baseline to Week 4, the least-squares mean of change from Baseline to Visit 4/Week 4 was -3.7 and -3.4 for placebo and MK 0524â€‰(100â€‰mg), respectively. The least-squares mean difference (placebo minus MK-0524) with 90% confidence interval of change in CEA score from Baseline to Visit 4/Week 4 was estimated as -0.3 (-1.6, 1.0). For the secondary endpoints, the least-squares mean difference (placebo minus MK-0524) with 90% confidence interval of change from Baseline to Visit 4/Week 4 was estimated as -0.7 (-7.7, 6.4) for PSA total score, -4.5 (-14.2, 5.3) for PSA emotion score, -1.3 (-7.8, 5.3) for PSA symptoms score, and 3.6 (-4.3, 11.4) for PSA functioning score. MK-0524 administered once daily for 4 weeks was generally well tolerated in this population of subjects with rosacea. However, there were no clinically meaningful changes in the primary endpoint of CEA given that the response to MK-0524 could not be differentiated from that to placebo. There was also no clinically meaningful change in the secondary endpoint, PSA. A DP1 antagonist is not likely to be effective in rosacea.PMID: 25142778 [PubMed - as supplied by publisher] http://www.ncbi.nlm.nih.gov/pubmed/25142778?dopt=Abstract = URL to article Link to comment Share on other sites More sharing options...
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!Register a new account
Already have an account? Sign in here.Sign In Now